Supplementary Figure S3 from Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

Tobias Keßler; Daniel Schrimpf; Laura Doerner; Ling Hai; Leon D. Kaulen; Jakob Ito; Martin J. van den Bent; Martin Taphoorn; Alba A. Brandes; Ahmed Idbaïh; Julien Dômont; Paul M. Clément; Mario Campone; Martin Bendszus; Andreas von Deimling; Felix Sahm; Michael Platten; Wolfgang Wick; Antje Wick

doi:10.1158/1078-0432.27033691

Abstract

Supplementary Figure 3: Characteristics of RTK1 tumors in comparison to RTK2 and MES. A Distribution of MGMT promotor methylation in main glioblastoma methylation subgroups. Classifier assignment is based on the v12.5 version (n = 295). Mutational profiles in B RTK1 tumors (n = 89), C RTK2 tumors (n = 140) and D MES tumors (n = 66).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Keßler et al. (2024) studied this question.

synapsesocial.com/papers/68e58589b6db6435875227a4 https://doi.org/10.1158/1078-0432.27033691

View at Publisher

Ask AI

Bookmark

Share

Supplementary Figure S3 from Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

Abstract

Discussion

Cite This Study

Supplementary Figure S3 from Prognostic markers of DNA methylation and NGS sequencing in progressive glioblastoma from the EORTC-26101 trial

Abstract

Discussion

Cite This Study

Keep reading

Keep reading